scRNA-seq can analyze the transcriptional characteristics of CAR-T cells to predict their functions: in CD19-CAR-T therapy, specific CD8+T cells and exhaustion markers before infusion are associated with treatment failure; in patients with large B-cell lymphoma, some/non-responders have defective CAR-T killing function due to abnormal tumor cell pathways. Here, CD8A is linked to neoplasm.